102 related articles for article (PubMed ID: 19836373)
1. The effect of genetic variability on drug response in conventional breast cancer treatment.
Wiechec E; Hansen LL
Eur J Pharmacol; 2009 Dec; 625(1-3):122-30. PubMed ID: 19836373
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics for individualized cancer chemotherapy.
Efferth T; Volm M
Pharmacol Ther; 2005 Aug; 107(2):155-76. PubMed ID: 15890408
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenomics in breast cancer: current trends and future directions.
Wajapeyee N; Somasundaram K
Curr Opin Mol Ther; 2004 Jun; 6(3):296-301. PubMed ID: 15264432
[TBL] [Abstract][Full Text] [Related]
5. Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.
Low SK; Kiyotani K; Mushiroda T; Daigo Y; Nakamura Y; Zembutsu H
J Hum Genet; 2009 Oct; 54(10):564-71. PubMed ID: 19696793
[TBL] [Abstract][Full Text] [Related]
6. Role of xenobiotic metabolizing gene polymorphisms in breast cancer susceptibility and treatment outcome.
Chacko P; Joseph T; Mathew BS; Rajan B; Pillai MR
Mutat Res; 2005 Mar; 581(1-2):153-63. PubMed ID: 15725614
[TBL] [Abstract][Full Text] [Related]
7. Single nucleotide polymorphisms in the multidrug resistance gene 1 (ABCB1): effects on its expression and clinicopathological characteristics in breast cancer patients.
Vaclavikova R; Nordgard SH; Alnaes GI; Hubackova M; Kubala E; Kodet R; Mrhalova M; Novotny J; Gut I; Kristensen VN; Soucek P
Pharmacogenet Genomics; 2008 Mar; 18(3):263-73. PubMed ID: 18300948
[TBL] [Abstract][Full Text] [Related]
8. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
9. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
[TBL] [Abstract][Full Text] [Related]
10. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer.
Bewick MA; Conlon MS; Lafrenie RM
Breast Cancer Res Treat; 2008 Sep; 111(1):93-101. PubMed ID: 17922231
[TBL] [Abstract][Full Text] [Related]
11. Prevalent breast cancer patients with a homozygous mutant status for CYP2D6*4: response and biomarkers in tamoxifen users.
Dieudonné AS; Lambrechts D; Claes B; Vandorpe T; Wildiers H; Timmerman D; Billen J; Leunen K; Amant F; Berteloot P; Smeets A; Paridaens R; Weltens C; Van Limbergen E; Van den Bogaert W; Vergote I; Van Huffel S; Christiaens MR; Neven P
Breast Cancer Res Treat; 2009 Dec; 118(3):531-8. PubMed ID: 19597703
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms in folate metabolizing enzymes and transport proteins and the risk of breast cancer.
Kotsopoulos J; Zhang WW; Zhang S; McCready D; Trudeau M; Zhang P; Sun P; Narod SA
Breast Cancer Res Treat; 2008 Dec; 112(3):585-93. PubMed ID: 18204969
[TBL] [Abstract][Full Text] [Related]
13. A haplotype analysis of HER-2 gene polymorphisms: association with breast cancer risk, HER-2 protein expression in the tumor, and disease recurrence in Korea.
Han W; Kang D; Lee JE; Park IA; Choi JY; Lee KM; Bae JY; Kim S; Shin ES; Lee JE; Shin HJ; Kim SW; Kim SW; Noh DY
Clin Cancer Res; 2005 Jul; 11(13):4775-8. PubMed ID: 16000574
[TBL] [Abstract][Full Text] [Related]
14. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
15. Genetics and genome-wide association studies: surgery-guided algorithm and promise for future breast cancer personalized surgery.
Roukos DH
Expert Rev Mol Diagn; 2008 Sep; 8(5):587-97. PubMed ID: 18785807
[TBL] [Abstract][Full Text] [Related]
16. Using genetic variation to optimize cancer chemotherapy.
McLeod HL; Papageorgio C; Watters JW
Clin Adv Hematol Oncol; 2003 Feb; 1(2):107-11. PubMed ID: 16224389
[TBL] [Abstract][Full Text] [Related]
17. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
18. Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients.
Fasching PA; Loehberg CR; Strissel PL; Lux MP; Bani MR; Schrauder M; Geiler S; Ringleff K; Oeser S; Weihbrecht S; Schulz-Wendtland R; Hartmann A; Beckmann MW; Strick R
Breast Cancer Res Treat; 2008 Nov; 112(1):89-98. PubMed ID: 18049890
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacogenomics: the quest for individualized therapy].
López-López M; Guerrero-Camacho JL; Familiar-López IM; Jung-Cook H; Corona-Vázquez T; Alonso-Vilatela ME
Rev Neurol; 2004 Dec 1-15; 39(11):1063-71. PubMed ID: 15597270
[TBL] [Abstract][Full Text] [Related]
20. MDR1 C3435T polymorphism in patients with breast cancer.
Turgut S; Yaren A; Kursunluoglu R; Turgut G
Arch Med Res; 2007 Jul; 38(5):539-44. PubMed ID: 17560460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]